Source 1primary paper2026MED
Toolkit/convection-enhanced delivery
convection-enhanced delivery
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
We then focus on bottlenecks such as target selection strategies, engineering design, and TME-driven issues like phenotypic inactivation and antigen escape, discussing corresponding optimization approaches like armoring modifications, logic-gated designs, and convection-enhanced delivery.
Usefulness & Problems
Why this is useful
Convection-enhanced delivery is presented as an optimization approach within the CAR-M translational strategy for GBM. In the abstract it appears specifically as a way to address delivery-related bottlenecks.; delivery optimization for CAR-M therapy in GBM
Source:
Convection-enhanced delivery is presented as an optimization approach within the CAR-M translational strategy for GBM. In the abstract it appears specifically as a way to address delivery-related bottlenecks.
Source:
delivery optimization for CAR-M therapy in GBM
Problem solved
It is included among approaches intended to improve translation of CAR-M therapy in the setting of GBM barriers.; addresses delivery bottlenecks in GBM translation
Source:
It is included among approaches intended to improve translation of CAR-M therapy in the setting of GBM barriers.
Source:
addresses delivery bottlenecks in GBM translation
Problem links
addresses delivery bottlenecks in GBM translation
LiteratureIt is included among approaches intended to improve translation of CAR-M therapy in the setting of GBM barriers.
Source:
It is included among approaches intended to improve translation of CAR-M therapy in the setting of GBM barriers.
Published Workflows
Objective: Translate CAR-M therapy for glioblastoma from preclinical concept toward early-phase clinical testing while prioritizing mechanistic validation.
Why it works: The proposed pathway is expected to work by using biomarker-supported mechanistic validation in early-phase clinical trials to answer fundamental questions about CAR-M homing, survival, and function in patients before broader efficacy claims are made.
tumor homingtumor microenvironment reprogrammingbridging innate and adaptive immunitymechanistic validationcombinatorial approachessmart technologiesbiomarker analyses
Stages
- 1.Mechanistic validation in early-phase clinical trials(confirmatory_validation)
The stage exists because the review identifies a translational gap and states that clinical efficacy in GBM remains unproven, so mechanistic questions in patients should be prioritized.
Selection: Use biomarker-supported early-phase clinical testing to answer fundamental biological questions about CAR-M homing, survival, and function in patients.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
Translation ControlTarget processes
selectiontranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationoperating role: delivery
The abstract only supports that it is a delivery strategy considered during CAR-M optimization for GBM. Specific hardware or procedural requirements are not described in the provided text.; used in the context of GBM-directed CAR-M translation
The abstract does not claim that convection-enhanced delivery alone resolves phenotypic inactivation, antigen escape, or the overall lack of proven clinical efficacy.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Despite promising preclinical data, clinical efficacy of CAR-M therapy in glioblastoma remains unproven.
However, despite promising preclinical data, clinical efficacy in GBM remains unproven.
The review identifies armoring modifications, logic-gated designs, and convection-enhanced delivery as optimization approaches for CAR-M translational bottlenecks in glioblastoma.
We then focus on bottlenecks such as target selection strategies, engineering design, and TME-driven issues like phenotypic inactivation and antigen escape, discussing corresponding optimization approaches like armoring modifications, logic-gated designs, and convection-enhanced delivery.
CAR-M therapy is presented as a promising therapeutic avenue for glioblastoma because of tumor-homing capacity, tumor microenvironment reprogramming, and the potential to bridge innate and adaptive immunity.
Chimeric antigen receptor macrophages (CAR-M) therapy presents a promising new avenue for GBM treatment, leveraging its inherent tumor-homing capacity, TME reprogramming function, and potential to bridge innate and adaptive immunity.
Approval Evidence
1 source1 linked approval claimfirst-pass slug convection-enhanced-delivery
We then focus on bottlenecks such as target selection strategies, engineering design, and TME-driven issues like phenotypic inactivation and antigen escape, discussing corresponding optimization approaches like armoring modifications, logic-gated designs, and convection-enhanced delivery.
Source:
optimization strategysupports
The review identifies armoring modifications, logic-gated designs, and convection-enhanced delivery as optimization approaches for CAR-M translational bottlenecks in glioblastoma.
We then focus on bottlenecks such as target selection strategies, engineering design, and TME-driven issues like phenotypic inactivation and antigen escape, discussing corresponding optimization approaches like armoring modifications, logic-gated designs, and convection-enhanced delivery.
Source:
Comparisons
Source-stated alternatives
Other optimization approaches named alongside it are armoring modifications and logic-gated designs.
Source:
Other optimization approaches named alongside it are armoring modifications and logic-gated designs.
Source-backed strengths
presented as an optimization approach for translational bottlenecks
Source:
presented as an optimization approach for translational bottlenecks
Compared with intranasal oxytocin
convection-enhanced delivery and intranasal oxytocin address a similar problem space because they share translation.
Shared frame: same top-level item type; shared target processes: translation; shared mechanisms: translation_control
Compared with lipid nanoparticles
convection-enhanced delivery and lipid nanoparticles address a similar problem space because they share selection, translation.
Shared frame: same top-level item type; shared target processes: selection, translation; shared mechanisms: translation_control
Strengths here: may avoid an exogenous cofactor requirement.
Relative tradeoffs: appears more independently replicated.
Compared with virus-like particles
convection-enhanced delivery and virus-like particles address a similar problem space because they share translation.
Shared frame: same top-level item type; shared target processes: translation; shared mechanisms: translation_control
Relative tradeoffs: appears more independently replicated; looks easier to implement in practice.
Ranked Citations
- 1.